• KOL
    • Lewy Bodies
    • James E Galvin
    • James E Galvin: Influence Statistics

      James E Galvin

      James E Galvin

      Show email address

      Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA | Comprehensive Center for Brain Health, ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      James E Galvin:Expert Impact

      Concepts for whichJames E Galvinhas direct influence:Lewy bodies,Alzheimer disease,Cognitive impairment,Lewy body,Quick dementia rating,Alzheimers disease,Parkinson disease,Lewy body dementia.

      James E Galvin:KOL impact

      Concepts related to the work of other authors for whichfor which James E Galvin has influence:Cognitive impairment,Lewy bodies,Alzheimer disease,Alpha synuclein,Older people,Fatty acids,Multiple atrophy.

      KOL Resume for James E Galvin

      Year
      2022

      Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA

      2021

      Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine

      University of Miami, Miami, FL, USA

      2020

      Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA

      Comprehensive Center for Brain Health, University of Miami, Miami, FL, 33136

      University of Miami, Miami, FL.

      2019

      Comprehensive Center for Brain Health, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton

      2018

      Institute for Healthy Aging, Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA

      Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States

      Co-author.

      2017

      Charles E. Schmidt College of Medicine at Florida Atlantic University, Boca Raton, Florida

      2016

      Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL

      Marcus Neuroscience Institute, Florida Atlantic University, Boca Raton, Florida, USA

      New York University

      2015

      Center for Cognitive Neurology, Departments of Neurology, Psychiatry, and Population Health, NYU Langone Medical Center.

      Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA.

      Department of Psychiatry, New York University School of Medicine, New York, NY, USA

      2014

      New York University Langone Medical Center, New York, New York, United States

      2013

      Comprehensive Center on Brain Aging, New York University Langone Medical Center, 145 East 32nd Street, New York, NY 10016, USA.

      Center of Excellence on Brain Ageing, New York University Langone Medical Centre, New York, United States

      New York University Langone School of Medicine New York New York USA

      2012

      Department of Neurology, New York University, New York, New York

      Sign-in to see all concepts, it's free!
      Sample of concepts for which James E Galvin is among the top experts in the world.
      Concept World rank
      lbd characterization dementia #1
      mci 13 individuals #1
      link monoamine oxidase #1
      testing dementia knowledge #1
      clas methods #1
      dysferlin distribution #1
      capgras lewy bodies #1
      busy physicians growing #1
      neighborhood greenspace mri #1
      disorders lewy #1
      dementia outcomes mindfulness #1
      transcriptional patterns mosaics #1
      sprague dopal #1
      mcaide ability #1
      unique position physicians #1
      frailty discussion #1
      greenspace brain #1
      burden major factors #1
      highly stochastic cross #1
      intraindividual 2–3 #1
      greater 32 decrease #1
      practical guidelines recognition #1
      treatments preventative actions #1
      bpsd hospitalized persons #1
      cellfree neuron cultures #1
      mcaide risk #1
      mosaics understanding #1
      stage fototest #1
      baseline patient function #1
      qdrs #1
      sex chs data #1
      cellfree cell cultures #1
      fcg responses #1
      699 eligible caregivers #1
      librarians data collection #1
      screening daily functioning #1
      cognition disorders activities #1
      quick dementia rating #1
      tissues comprehensive evaluation #1
      pg12 specific #1
      nmethyldaspartate stroke huntington #1
      subdomainspecific analyses #1
      aging paradigms #1
      patients dementia types #1
      depression capgras #1
      plm transitions #1
      dementia screening program #1
      mci adrd screening #1
      missing driver #1
      greenspace mri #1
      Sign-in to see all concepts, it's free!

      Prominent publications by James E Galvin

      KOL-Index: 15151

      BACKGROUND: Dementia and mild cognitive impairment (MCI) are underrecognized in community settings. This may be due in part to the lack of brief dementia screening tools available to clinicians. We compared 2 brief, informant-based screening tests: the AD8 and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) in a community-based neurology practice in the midwestern United States.

      METHODS: We examined 186 consecutive patients (44 controls, 13 with MCI, and 129 with ...

      Known for Mci Dementia | Ad8 Iqcode | Cognitive Impairment | Informant Questionnaire | Specificity Surveys
      KOL-Index: 14877

      CONTEXT: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.

      OBJECTIVE: To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease.

      DESIGN, SETTING, AND PATIENTS: A randomized, ...

      Known for 18 Months | Dha Placebo | Docosahexaenoic Acid | Alzheimer Disease | Brain Atrophy
      KOL-Index: 14450

      BACKGROUND: Cognitive dysfunction, including dementia and delirium, is prevalent in geriatric emergency department (ED) patients, but often remains undetected. One barrier to reliable identification of acutely or chronically impaired cognitive function is the lack of an acceptable screening tool. While multiple brief screening instruments have been derived, ED validation trials have not previously demonstrated tools that are appropriately sensitive for clinical use.

      OBJECTIVES: The ...

      Known for Cognitive Dysfunction | Ottawa 3dy | Short Blessed Test | Geriatric Patients | Screening Tools
      KOL-Index: 12207

      Screening tests for Alzheimer's disease lack sensitivity and specificity. We developed the AD8, a brief dementia screening interview validated against clinical and cognitive evaluations, as an improvement over current screening methods. Because insufficient follow-up has occurred to validate the AD8 against the neuropathologic findings of Alzheimer's disease, we investigated whether AD8 scores correspond to impairment in episodic memory testing and changes in biomarkers of Alzheimer's ...

      Known for Dementia Screening | Alzheimers Disease | Ad8 Scores | Informantbased Assessments | Biomarkers Alzheimer
      KOL-Index: 11619

      BACKGROUND: Extrapyramidal signs (EPS) are common in Alzheimer disease (AD) and increase in prevalence as AD advances. The neuropathologic substrate responsible for EPS in AD remains to be fully characterized.

      METHODS: Subjects had a clinical diagnosis of AD confirmed by neuropathologic examination. EPS during life were documented by clinical methods assessing bradykinesia, cogwheel rigidity, rest tremor, and parkinsonian gait. Subjects with EPS and previous neuroleptic exposure were ...

      Known for Alzheimer Disease | Substantia Nigra | Extrapyramidal Signs | Pathology Tau | Dementia Severity
      KOL-Index: 10942

      OBJECTIVE: To establish the validity, reliability, and discriminative properties of the AD8, a brief informant interview to detect dementia, in a clinic sample.

      METHODS: We evaluated 255 patient-informant dyads. We compared the number of endorsed AD8 items with an independently derived Clinical Dementia Rating (CDR) and with performance on neuropsychological tests. Construct and concurrent validity, test-retest, interrater and intermodal reliability, and internal consistency of the AD8 ...

      Known for Informant Interview | Validity Reliability | Neuropsychological Tests | Ad8 Scores | Discriminative Properties
      KOL-Index: 10838

      Recently, alpha-synuclein was shown to be a structural component of the filaments in Lewy bodies (LBs) of Parkinson's disease (PD), dementia with LBs (DLB) as well as the LB variant of Alzheimer's disease, and this suggests that alpha-synuclein could play a mechanistic role in the pathogenesis of these disorders. To determine whether alpha-synuclein is a building block of inclusions in other neurodegenerative movement disorders, we examined brains from patients with multiple system ...

      Known for Glial Cytoplasmic Inclusions | White Matter | Alpha Synuclein | Atrophy Brains | Neurodegenerative Disorders
      KOL-Index: 10793

      BACKGROUND: To understand the earliest signs of cognitive decline caused by Alzheimer disease (AD) and other illnesses causing dementia, information is needed from well-characterized individuals without dementia studied longitudinally until autopsy.

      OBJECTIVE: To determine clinical and cognitive features associated with the development of AD or other dementias in older adults.

      DESIGN: Longitudinal study of memory and aging.

      SETTING: Alzheimer's Disease Research Center, St Louis, Mo.

      MAIN ...

      Known for Alzheimer Disease | Individuals Dementia | Practice Effects | Cognitive Decline | Outcome Measures
      KOL-Index: 10362

      BACKGROUND: Dementia caregivers describe knowing what to expect as an unmet need and many are unaware that dementia can be a terminal condition. Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia with unique features which may affect the end of life (EOL). Given the paucity of data on EOL experiences in dementia and unique aspects of DLB affecting EOL, we investigated EOL experiences as reported by caregivers of individuals with DLB.

      METHOD: We conducted telephone ...

      Known for Lewy Bodies | Life Experiences | Eol Dlb | Caregivers Individuals | Telephone Interviews
      KOL-Index: 10347

      OBJECTIVE: To determine which clinical features best characterize Parkinson disease dementia (PDD), compared with Alzheimer disease (AD) and dementia with Lewy bodies (DLB), and to determine the pathologic basis for PDD.

      METHODS: We examined 103 participants enrolled in a longitudinal study (nondemented control = 10, PD = 42, DLB = 20, AD = 31) who were followed to autopsy using standardized protocols. We characterized the features of PDD using published criteria for AD and DLB as a ...

      Known for Disease Dementia | Pdd Dlb | Clinical Phenotype | Visual Hallucinations | Lewy Bodies
      KOL-Index: 9866

      INTRODUCTION: Test the validity and reliability of the Quick Dementia Rating System (QDRS), a rapid dementia staging tool.

      METHODS: The QDRS was tested in 267 patient-caregiver dyads compared with Clinical Dementia Ratings (CDR), neuropsychological testing, and gold standard measures of function, mood, and behavior. Psychometric properties including, item variability, floor and ceiling effects, concurrent and construct validity, and internal consistency were determined. The QDRS was used ...

      Known for Quick Dementia Rating | Dementia Staging | Gold Standard Measures | Qdrs Cdr | Internal Consistency
      KOL-Index: 9629

      Neurodegeneration with brain iron accumulation, type 1 (NBIA 1), or Hallervorden-Spatz syndrome, is a rare neurodegenerative disorder characterized clinically by Parkinsonism, cognitive impairment, pseudobulbar features, as well as cerebellar ataxia, and neuropathologically by neuronal loss, gliosis, and iron deposition in the globus pallidus, red nucleus, and substantia nigra. The hallmark pathological lesions of NBIA 1 are axonal spheroids, but Lewy body (LB)-like intraneuronal ...

      Known for Brain Iron Accumulation | Triton X100 | Beta Synuclein | Type 1 | Lewy Body
      KOL-Index: 9440

      OBJECTIVE: To test the ability of patients to rate their own cognitive ability using the AD8 compared with informant and clinician ratings of cognitive status.

      DESIGN, SETTING, AND PATIENTS: The AD8 was administered to 325 consecutive participant-informant dyads enrolled in a longitudinal study at Washington University School of Medicine between April 4, 2005, and December 15, 2005. The number of AD8 items endorsed by the participant was compared with informant answers and an ...

      Known for Cognitive Ability | Demented Individuals | Informant Ad8 | Clinical Dementia Rating | Correlation Coefficients
      KOL-Index: 9429

      PURPOSE: Patients with Lewy body dementia (LBD) may present a unique set of symptoms and challenges to family caregivers compared with other types of dementia. Prominent difficulties include motor impairment, activities of daily living (ADLs) disability, recurrent behavioral and emotional problems (BEPs), and diagnostic difficulties. These problems are likely to affect caregivers' subjective burden.

      DESIGN AND METHODS: The present study used data from an Internet survey conducted by the ...

      Known for Lewy Body Dementia | Burden Caregivers | Patients Lbd | Daily Living Adaptation | Stress Psychological
      KOL-Index: 9241

      OBJECTIVE: To determine whether dementia with Lewy bodies (DLB) progresses more rapidly than Alzheimer disease (AD).

      METHODS: We compared 315 participants (63 with DLB and 252 with AD) enrolled in a prospective longitudinal study of memory and aging with annual clinical and cognitive assessments and followed until death. The main outcome measure was dementia progression to institutionalization and death. Neuropathologic examinations were performed on all participants in this study. ...

      Known for Alzheimer Disease | Lewy Bodies | Patients Dlb | Cognitive Decline | Dementia Progression

      Key People For Lewy Bodies

      Top KOLs in the world
      #1
      Dennis, W Dickson
      lewy bodies alzheimer disease frontotemporal dementia
      #2
      John Q Trojanowski
      alzheimer disease lewy bodies tau pathology
      #3
      Ian Grant McKeith
      lewy bodies visual hallucinations alzheimers disease
      #4
      Clive G Ballard
      lewy bodies alzheimer disease vascular dementia
      #5
      Robert Henry Perry
      lewy bodies alzheimers disease senile dementia
      #6
      John Tiernan T O'Brien
      lewy bodies alzheimers disease white matter

      Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA | Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Miami,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.